Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. (SRNE): 5 pipeline candidates · ~5 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.2 months
D/E -3.19 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Sorrento Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$386K
Cash
$69.7M
Quarterly Burn
$55.7M
Runway
5.2 mo
Revenue
$15.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| ovydso | Phase 2 |
| resiniferatoxin | Phase 2 |
| semdexa | Phase 3 |
| sti-1492 | Phase 1 |
| sti-1557 | Preclinical |
Frequently asked questions
How many drug candidates are in Sorrento Therapeutics, Inc.'s pipeline?
Sorrento Therapeutics, Inc. (SRNE) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sorrento Therapeutics, Inc.'s lead drug candidate?
Sorrento Therapeutics, Inc.'s most advanced tracked candidate is ovydso (Phase 2) for COVID-19.
What is Sorrento Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sorrento Therapeutics, Inc. has approximately 5.2 months of cash runway.
What is Sorrento Therapeutics, Inc.'s market capitalization?
Sorrento Therapeutics, Inc.'s market capitalization is approximately $386K.
Who is the CEO of Sorrento Therapeutics, Inc.?
Dr. Henry H. Ji Ph.D. is the chief executive officer of Sorrento Therapeutics, Inc. (SRNE).
Get the full picture on Sorrento Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.